Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX-4TZT
- Development stage
- Phase 2
- Lead developer
- MEDRx
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
MRX-4TZT is a transdermal patch formulation of tizanidine, a centrally acting alpha-2 adrenergic agonist used as a muscle relaxant. Developed by MEDRx using its proprietary Ionic Liquid Transdermal System (ILTS) technology, the patch is designed to provide sustained blood concentrations of the drug while minimizing systemic side effects such as drowsiness, which are commonly associated with oral tizanidine. The drug is primarily being developed for the management of spasticity. In 2017, Cipla USA entered into a licensing agreement with MEDRx for the development and commercialization of the product outside of East Asia.
- Other names
- Tizanidine patchTizanidine transdermal systemTizanidine tape
02
Targets
ADRA2A (α2A)
Beyond the preview
Go deeper on MRX-4TZT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX-4TZT.